Effect of Propranolol on Elevated Arterial Blood Pressure
|
|
- Stephany Walters
- 5 years ago
- Views:
Transcription
1 Effect of Propranolol on Elevated Arterial Blood Pressure By DAVI W. RICHARDSO, M.D., JACK FREUD, M.D., ARTHUR S. GEAR, M.D., H. PAGE MAUCK, JR., M.D., AD LESTER W. PRESTO, B.S. Downloaded from by guest on July 5, 218 SUMMARY ineteen patients with moderately severe arterial hypertension received propranolol (12 mg daily), or chlorthalidone (1 mg daily), both medications together, and placebos in a double-blind crossover trial. Each treatment was given for 5 weeks; blood pressure was measured at weekly intervals. Propranolol alone reduced arterial pressure by 9/8 mm Hg, a statistically insignificant change. Use of chlorthalidone alone was accompanied by an average reduction in arterial blood pressure of 23/9 mm Hg. Both drugs together lowered blood pressure by 33/15 mm Hg. Heart rate was lower in regimens including propranolol; body weight and serum potassium and chloride concentration were lower and blood urea nitrogen and serum creatinine were higher in regimens containing chlorthalidone. Propranolol, in the dose given, is a less effective hypotensive drug than is chlorthalidone. Additional Indexing Words: Hypertension Chlorthalidone Potassium supplementation Weight PROETHALOL, an effective beta-adrenergic blocking agent, was observed to reduce arterial blood pressure in hypertensive patients being treated for angina pectoris.1 Subsequently Prichard and Gillam2 3 compared propranolol, another beta-adrenergic blocking drug, 12 to 64 mg/day, with previously administered methyldopa in 12 hypertensive patients and reported lower blood pressure during use of propranolol. Since in previous clinical trials2-6 the hypotensive effect of propranolol was not compared with that of placebo, we have evaluated the hypotensive efficacy of propranolol in comparison with that of inert tablets and a standard diuretic in trials in which neither physician nor pa- From Departments of Medicine and Biometry, Medical College of Virginia, Richmond, Virginia. Work was supported by grants from the Virginia Heart Association and from Ayerst Laboratories and Geigy Pharmaceuticals. Presented at the Fortieth Scientific Sessions of the American Heart Association, San Francisco, California, October 21, Beta-adrenergic blockade Blood chemistry Heart rate tient knew which therapy was being administered. We have compared propranolol, 12 mg/day, placebo, chlorthalidone, 1 mg/ day, and the combination of propranolol and chlorthalidone as hypotensive agents in 19 hypertensive patients. The order of administration of drugs was randomized and unknown to patient or physician. Propranolol, 12 mg/ day, had only moderate hypotensive effect. Methods Twenty-two patients entered the study. One refused to return after the first week, one died 2 weeks before completion of the fourth period, and one was stopped before entering the fourth period which would have included chlorthalidone and potassium, a combination withdrawn by its manufacturer because of toxicity. Thus 19 patients, 5 male and 14 female, completed the entire study. The patients' ages ranged from 35 to 69 years. T.C., a 44-year-old egro man, had chronic nephritis manifest by persistent proteinuria, microscopic hematuria, cylinduria, and azotemia without pyuria or bacteriuria. G.W., a 57-year-old egro woman, had probable hyperparathyroidism, with intermittent hypercalcemia, a renal stone, and recurrent duodenal ulcer. She
2 PROPRAOLOL AD ELEVATED BLOOD PRESSURE 535 Downloaded from by guest on July 5, 218 did not have azotemia or infected urine. In the remainder, no cause for hypertension could be demonstrated despite multiple urinalyses, determination of urinary catecholamine excretion, intravenous pyelography, radioactive renography, multiple determinations of serum sodium, potassium, chloride and bicarbonate concentrations, and complete historical and physical examination. one of the patients had hemorrhagic or exudative retinopathy, congestive heart failure, edema, asthma, or gout. Six had chemical diabetes mellitus; none received insulin. Each patient had been followed in the hypertension clinic for months, and each had previously received antihypertensive drugs. Each had diastolic blood pressure averaging 88 mm Hg or more during five weekly visits while receiving placebo tablets, save for one patient whose blood pressure averaged 143/8 mm Hg prior to randomization and 15/85 during the randomization placebo period. All patients carried on their usual work without restriction of diet or exercise. Each patient was seen at weekly intervals for 3 weeks. At each visit the patient was weighed and arterial pressure was recorded by one of two nurses who made all measurements throughout the study. Patients lay for 1 minutes in a quiet room, after which blood pressure was measured three times in the supine position and three times in the standing position. Heart rate was recorded with the patients supine. Pills remaining in the bottles issued the previous week were counted in an attempt to ensure that medication was taken properly, and the patient was reminded how to take the medications. At 3- week intervals, blood was drawn for hemoglobin concentration, white cell count, autoanalyzer estimation of urea nitrogen and of serum concentrations of creatinine, sodium, potassium, chloride, bicarbonate, bilirubin, alkaline phosphatase and glutamic-oxalacetic transaminase. At the first five weekly visits, each patient received sufficient medicaments for him to take one dummy capsule of chlorthalidone twice daily and one dummy tablet of propranolol three times daily in the ensuing week. Thereafter, each received treatment for 5 weeks with each of the four possible combinations: (1) both medications dummy; (2) both active (propranolol, 4 mg for use thrice daily, and chlorthalidone, 5 mg for use twice daily); (3) active chlorthalidone, 5 mg for use twice a day and dummy pro- Table 1 Comparison of Arterial Pressures in Lying Position Between the Initial Placebo Period (Single-Blind) and the Treatment Placebo Period* (Randomized; Double-Blind) Age Treatment Systolic (mm Hg) Diastolic (mm Hg) Patient (yr) Sex Race placebo period Initial Treatment Initial Treatment D.C. J.H. L.G. M.T. G.W. P.A. T.C. S.M. P.T. E.P. C.H. C.B. L.S. P.H. A.R. M.C. L.W. E.A. C.A. 4 F 49 M 4 F 35 F 49 F 55 M Average for period 45 M 52 F 43 F 5 F Average for period 44 F 67 F 54 M 69 F 37 F 55 F Average for period 49 F 45 F 46 M Average for period Overall averages *Period = 5 weeks. w Second Second Second Second Fourth Fourth Fourth (177.8) (17.6) (163.) (177.1) (171.5) (18.9) (166.9) (162.8) (178.3) (172.3) (15.5) (14.3) (13.1) (18.7) (15.) (11.) (13.9) (14.7) (18.1) (16.7)
3 536 RICHARDSO ET AL. Arterial Blood Pressure-Lying Table 2 Position Downloaded from by guest on July 5, 218 Treatment week Dummy* Propranololt Chlorthalidonet Propranolol plus chlorthalidone Dummy Propranolol Chlorthalidone Propranolol plus chlorthalidone Second week week Systolic pressure Diastolic pressure Fourth week Fifth week Means not connected by vertical lines are significantly different (P <.5). *1 inert tablet resembling propranolol three times daily plus 1 inert tablet resembling chlorthalidone twice daily. tpropranolol, 4 mg, three times daily plus 1 dummy chlorthalidone tablet twice daily. *Chlorthalidone, 5 mg, and KC1,.5 g, twice daily plus 1 dummy propranolol tablet three times daily. Propranolol, 4 mg, three times daily plus chlorthalidone, 5 mg, twice daily. Table 3 Average Arterial Blood Pressure-Standing Position Treatment week Second week week Systolic pressure Dummy* Propranololt Chlorthalidonet Propranolol plus chlorthalidone Diastolic pressure Dummy Propranolol Chlorthalidone Propranolol plus chlorthalidone Fourth week Fifth week Means not connected by vertical lines are significantly different (P <.5). *1 inert tablet resembling propranolol three times daily plus 1 inert tablet resembling chlorthalidone twice daily. tpropranolol, 4 mg, three times daily plus 1 dummy chlorthalidone tablet twice daily. *Chlorthalidone, 5 mg, and KC1,.5 g, twice daily plus 1 dummy propranolol tablet three times daily. Propranolol, 4 mg, three times daily plus chlorthalidone, 5 mg, twice daily.
4 Downloaded from by guest on July 5, 218 PROPRAOLOL AD ELEVATED BLOOD PRESSURE 537 pranolol; and (4) dummy chlorthalidone and active propranolol, 4 mg for use thrice daily. The tion to the experimental procedure. drugs, rather than lapse of time or habitua- order of administration was randomized and unknown to patient and observers. During the The blood pressure associated with each period when chlorthalidone was given without regimen is summarized in tables 2 and 3 and propranolol, potassium chloride, 5 mg, was figure 1. Propranolol, 4 mg three times a added to each chlorthalidone capsule in order day, reduced blood pressures with the patient to observe the effect of potassium supplementation on serum potassium concentration. Blood Hg, systolic and diastolic, as compared with in the lying down position by 9 and 8 mm pressure during that period in the double-blind crossover in which the patient received both placebo. Statistically significant reduction in dummies was used as the control pressure, diastolic pressure attributable to propranolol against which drug effects were compared. Analysis of variance for a randomized block design7 was no evidence of greater hypotensive effect occurred only in 2 of the 5 weeks. There (that is, each patient was considered as a complete block) was performed separately for each in the fifth than in the first week of propranolol administration. Chlorthalidone alone, 5 treatment period and each variable. Subsequently, Duncan's multiple-range test8 was used to mg twice a day, reduced pressure an average determine the statistical significance of the observed response differences among all treatment LYIG pairs. All patients were interviewed at each visit, after blood pressure and pulse had been recorded. 17r - *'----. o special effort was made to have a particular physician interview a x ---- particular patient throughout the study; in fact, each patient was seen by 16 H x ~x all four physicians at some time. Physicians were dv oe Ke instructed to ask at each visit about anv discomfort or change in daily habit; about sleepiness, 15 H A diarrhea, shortness of breath, swelling, and dizziness; and to record all symptoms. At the end of the study, all recorded symptoms were tabulated -o 14 H by study period without knowledge of which LALJ drug was received in any period. They were then retabulated by drug regimen. 3 (1) *-* Dummy Results x--x Propronolol A-A Chlorthalidone Effects on Arterial Pressure 12 H o--o P a C The effect on blood pressure of the ~: patients' KR habituation to the examination was observed I I1O by comparing the average pressure during the initial 5-week pre-randomization period of placebo administration with the average 1 X. - pressure during the "treatment" 5-week period in the double-blind trial in which the * - o_ X. patient received placebos. Table 1 shows the 9 data for each patient. In none of the four IE placebo periods during the double-blind comparison was the group average pressure sig WEEKS OF TREATMET nificantly different from the average pressure Figure 1 during the pre-randomization period. It is Arterial pressure, recorded in the supine position, on thus reasonable to assume that the changes each regimen. Each point is the average for 19 patients. The four regimens were placebo, propranolol, in blood pressure observed during administration of active drugs are the result of the pranolol plus chlorthalidone 12 mg daily, chlorthalidone, 1 mg daily, and pro- (P&C).
5 538 RICHARDSO ET AL. 2 * - Lying o - Standing + 1 o Downloaded from by guest on July 5, 218 i44 (5). (I) _ -3 _ -4 _ Zrz. -5 _- -6 _- * a I 88 * 8-7 _ Propronolol 4mg/ tid I & a 8 Chlortholidone 5mg / bid. m m S. 8 Propronolol Chlortholidone Figure 2 The changes in systolic arterial pressure observed in individual patients during active drug regimens. The horizontal line at zero represents each patient's pressure during the second through fifth weeks of placebo medication in the double-blind trial. Each point represents the change in blood pressure observed in one patient during the second through the fifth week on the indicated regimen, and is the mean of 12 measurements, three each week. Closed circles show changes in supine and open circles changes in standing blood pressure. of 23/9 mm Hg as compared with the placebo. Propranolol and chlorthalidone together reduced pressure an average of 33/15 mm Hg below that observed during administration of the placebo. Blood pressure was not significantly lower during administration of propranolol and chlorthalidone together than with chlorthalidone alone. The effects of drug regimens on blood pressure in the standing position were similar to those observed in the supine position (tables 2 and 3). Figures 2 and 3 show the changes of systolic and diastolic
6 PROPRAOLOL AD ELEVATED BLOOD PRESSURE 539 ffi +1~ r- LAJ 1~ IH -1 IF -2 I 8 1 o I 8 oo _ S fb *~~ ~ 8 9. *. A v v 8 % Downloaded from by guest on July 5, j (-4 * - Lying o - Standing Propronolol 4mg/tid Changes in diastolic arterial pressure regimens. See legend for figure 2. Heart Rate in Treatment Period week Second week Drug HR Drug HR C 79.2 C 83.9 D 76.8 D 75.1 C+P 71.3 C+P 68.6 P 65. P 65.8 Chlorthalidone 5mg /bid Figure 3 observed in individual patients during active drug Table 4 8 Propronolol Chlortholidone Fourth week Fifth week week Drug HR Drug HR (Incomplete C 84.1 C 77.8 data not D 76.4 D 77.4 analyzed) C + P 66.2 C + P 68.2 P 64.1 P 67.6 Means not connected by the same vertical line are significantly different (P <.5)- Duncan's multiple range test. Abbreviations: HR = heart rate; D = dummy; P = propranolol; C = chlorthalidone; and C + P = chlorthalidone plus propranolol. pressure in individual patients associated with each active drug regimen. Heart Rate, Weight, and Blood Chemistry The heart rate was consistently lower in the two regimens which included propranolol (table 4). Sinus rhythm was present in all subjects throughout the study. In each week of the treatment period, there was a significant (P <.5) difference among the body weights (table 5). For all treatment weeks the weights during the two chlorthali-
7 54 RICHARDSO ET AL. Weight (lb) in Treatment Period Table 5 week Second week week Drug Weight Drug Weight Drug Weight P P P D D D 166. C 163. C+P C + P C + P C C Fort wee Fourth week Drug Weight P D C+P C Fitwe Fifth week Drug Weight P D C+P C Means not connected by the same vertical line are significantly different (P <.5) Duncan's multiple range test. Abbreviations: D = dummy; P - propranolol: C -- chlorthalidone; and C + P - chlorthalidone plus propranolol. Downloaded from by guest on July 5, 218 Clinical Laboratory Data: Fifth Table 6 Week of Each Treatment Period Blood urea nitrogen Chloride Biliruhin, direct Blood urea nitrogen Bilirubin, direct (mg/1 ml) C+P 25.2 C 24. P 2. D 18.4 Creatinine (mg/1 ml) C+P 1.56 C 1.52 P 1.38 D 1.35 Sodium (meq / L) D p 143. CC+P Potassium (meq / L) p 4.31 D 4.28 C 3.9 C+P Chloride (meq/l) P 13.3 D 13.2 C 99.8 C+P 99.5 Carbon dioxide (mm/l) C+P 26.4 C 26.3 D 25.5 P 25.4 SGOT (Karmen units) C+P 21.3 C 2.6 D 19. P 18.4 Alkaline phosphatase (Bessey-Lowry units) P 1.69 C 1.47 C+ P 1.42 D 1.29 (mg/1 ml) C+P.17 P.94 C.6 D.58 Bilirubin, total (mg! 1 ml) C+P.334 P.321 C.31 D.27 count White cell (cell / mm3) P 6952i D 6511 C 6327 C+P 628 Hemoglobin (gl 1 ml) C D C+P P Means not connected by the same vertical line are significantly differenct (P <.5)- Duncan's multiple range test. Abbreviations: D - dummy; P - propranolol; C - chlorthalidone; and C + P - chlorthalidone plus propranolol. done regimens were slightly less, but the rum potassium and chloride were lower. There statistical significance of these differences was no difference between the serum potaswas more definitive in the earlier weeks. sium levels for the chlorthalidone regimen Blood chemical and hematological analy- and for the combined chlorthalidone and proses are shown in table 6. During the adminis- pranolol regimen; in the former regimen,.5 g tration of the two chlorthalidone regimens, of potassium chloride was incorporated into concentration of blood urea nitrogen and each capsule of chlorthalidone. serum creatinine were higher; those for se- o significant differences among the four Circulation, Volume XXXVII, April 19(38
8 PROPRAOLOL AD ELEVATED BLOOD PRESSURE 541 Possible Side Effects Table 7 Downloaded from by guest on July 5, 218 Symptom Headache Dizziness Dyspnea Cough and wheezing Fatigue Sleepiness ausea Placebo o. * Pt. t Propranolol o. Pt *o. = umber of times symptom was recorded. tpt. - umber of patients who developed this symptom. regimens were noted with respect to blood hemoglobin, white cell count, serum carbon dioxide content, bilirubin concentration, nor serum glutamic-oxalacetic transaminase and alkaline phosphatase. Side Effects Table 7 presents the number of times a symptom occurred during each regimen, and the number of patients who experienced each symptom. Headache occurred most frequently during placebo administration and least frequently in regimens containing chlorthalidone. Dizziness, on the other hand, occurred least frequently during the placebo period, and most frequently during administration of chlorthalidone. Dyspnea, cough, and wheezing occurred more frequently in regimens containing propranolol, with or without chlorthalidone. Fatigue occurred more often with regimens containing chlorthalidone or propranolol than with placebo. Other recorded symptoms, mentioned by only one or two patients each, included nocturia, present in all four regimens; angina pectoris, also present in all four regimens; urinary urgency, diarrhea, indigestion, nocturnal leg cramps, and stuffy nose. Discussion Propranolol in a dose of 4 mg three times daily caused an average blood pressure reduction of 9 mm Hg systohic and 8 mm Hg diastolic. These changes are statistically insignificant. The modest effect of propranolol is similar to that found by Waal,4 who ob Chlorthalidone and KC1 o. Pt Propranolol and chlorthalidone o. Pt served an average decrease in blood pressure of 12/6 mm Hg when propranolol, 45 to 15 mg/day, was added to other antihypertensive medication in 89 hypertensive patients. Similarly, Richards5 found an average decrease in pressure of 11/12 mm Hg in nine patients with elevated arterial pressure during administration of propranolol, 15 to 3 mg/day for 8 to 15 weeks. Paterson and Dollery6 compared the effects of propranolol, 8 mg/ day, propranolol, 24 mg/day, and hydrochlorthiazide, 5 mg/day, on 11 hypertensive patients who received each regimen for 6 weeks. Arterial pressure (lying) was 13/5 mm Hg higher with propranolol, 24 mg/day, and 14/6 mm Hg higher with propranolol, 8 mg/ day, than with hydrochlorthiazide. Though Prichard and Gillam3 have suggested that prolonged administration (4 weeks or more) of propranolol produces greater reduction of arterial pressure than is seen in the first 3 weeks, our results with those of Waal4 and of Paterson and Dollery6 show no greater hypotensive effect after 5 or 6 weeks of propranolol than after 1 to 3 weeks. Addition of potassium chloride,.5 g twice a day, to chlorthalidone had no noticeable effect on serum potassium concentration. Thus, there seems little reason for administration of capsules combining potassium, at least in this dose, with chlorthalidone. Analysis of side effects suggests that reduction in blood pressure lessened the prevalence of headache in this group of patients
9 Downloaded from by guest on July 5, with mild to moderate hypertensive disease. The greater frequency with which dyspnea and wheezing occurred while patients were taking propranolol is in keeping with known effects of the drug, which blocks adrenergic bronchodilation and, by reducing adrenergic stimulation of the heart, favors cardiac decompensation. In no patient were symptoms severe enough to require alteration of medication. One patient died in the fourth week period of the study, while taking propranolol alone. She was a 52-year-old egress with recurrent ventral hernia which had previously been repaired surgically without prolonged success. The hernia protruded one day, producing pain and vomiting for 2 hours, and then reduced itself spontaneously. She stopped taking propranolol that day. Two days later the hernia protruded again, and she entered the hospital with abdominal pain, vomiting, and hypotension. The hernia could not be reduced. Shock and puhnonary edema followed, and the patient died 36 hours later with continued pulmonary edema. Permission RICHARDSO ET AL. for autopsy was not given. The contribution of propranolol to her death is uncertain. Infusion of isoproterenol resulted in tachycardia and reduction in arterial pressure, suggesting that beta-adrenergic blockade was not present. References 1. PRIcEun, B.. C.: Hypotensive action of pronethalol. Brit Med J 1: 1227, PmcHARw, B.. C., AD GILLAM, P. M. S.: Use of propranolol in the treatment of hypertension. Brit Med J 2: 725, PiCuHARD, B.. C., AD GILLAM, P. M. S.: Propranolol in hypertension. Amer J Cardiol 18: 387, WAAL, H. J.: Hypotensive action of propranolol. Clin Pharmacol Ther 7: 588, RcHADs, F. A.: Propranolol in hypertension. Amer J Cardiol 18: 384, PATERSO, J. W., AD DOLLERY, C. T.: Effect of propranolol in mild hypertension. Lancet 2: 1148, BAILEY,. T. J.: Statistical Methods in Biology. London, English Universities Press, 1959, p STEEL, R. G. D., AD ToRRIE, J. H.: Principles and Procedures of Statistics. ew York, McGraw-Hill Book Co., 196, p. 17. Circulation, Volume XXXVII, Aprl 1968
10 Effect of Propranolol on Elevated Arterial Blood Pressure DAVID W. RICHARDSO, JACK FREUD, ARTHUR S. GEAR, H. PAGE MAUCK, JR. and LESTER W. PRESTO Downloaded from by guest on July 5, 218 Circulation. 1968;37: doi: /1.CIR Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX Copyright 1968 American Heart Association, Inc. All rights reserved. Print ISS: Online ISS: The online version of this article, along with updated information and services, is located on the World Wide Web at: Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document. Reprints: Information about reprints can be found online at: Subscriptions: Information about subscribing to Circulation is online at:
The antihypertensive and diuretic effects of amiloride and. of its combination with hydrochlorothiazide
The antihypertensive and diuretic effects of amiloride and of its combination with hydrochlorothiazide The hypotensive effect as well as changes in serum electrolytes and uric acid of amiloride (AM) and
More informationNursing Process Focus: Patients Receiving Dextran 40 (Gentran 40)
Assess for presence/history of hypovolemia, shock, venous thrombosis. Assess vital signs: Hypovolemic shock secondary to surgery, burns, hemorrhage, other serious condition PT and PTT abnormalities Venous
More informationPHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker
PACKAGE INSERT Pr PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker ACTIONS AND CLINICAL PHARMACOLOGY Phentolamine produces an alpha-adrenergic
More informationDiazoxide in the Treatment CLARENCE L. GANTT, M.D. which suggest that diazoxide may be the. drug of choice in the treatment of all forms
Intravenous Use o;f Diazoxide in the Treatment of Severe Hypertension By WILLIAM M. HAMBY, M.D., GERALD J. JANKOWSKI, M.D., J. MAURICE POUGET, M.D., GEORGE DUNEA, M.D., AND CLARENCE L. GANTT, M.D. SUMMARY
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationPractolol and bendrofluazide in treatment of hypertension
British Heart Journal, I974, 36, 867-87I. Practolol and bendrofluazide in treatment of hypertension D. B. Galloway, A. G. Beattie, and J. C. Petrie From Department of Therapeutics and Clinical Pharmacology,
More informationUrinary Kallikrein Excretion in Hypertensive Man
Urinary Kallikrein Excretion in Hypertensive Man RELATIONSHIPS TO SODIUM INTAKE AND SODIUM-RETAINING STEROIDS By Harry S. Margolius, David Horwttz, John J. Pisano, and Harry R. Kelser ABSTRACT Urinary
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D.
DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE Jules B. Puschett, M.D. Diuretic Resistance A clinical circumstance in which patients do not respond to a combination of salt restriction and even large
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary materials
Supplementary materials Table S Adverse events identified by participants diary logs and blood hematologic and biochemical tests (n=2) group (n=) Placebo group (n=) P value for chi-squared test Asthma
More informationPatient Interview Form
Page 1 of 5 Patient Interview Form Patient Information First Name: MRN: Last Name: Date Of Birth: Contact Preference Email Telephone call- Work Telephone call - Home Email Please check one as your preferred
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationNEUROLOGICAL SURGERY, P.C.
NEUROLOGICAL SURGERY, P.C. PATIENT INFORMATION Name Date of Birth Age Address City Sate NY Zip Home ( ) - Cell ( ) - Work ( ) - Ext: Email Address _ Sex M F Soc. Sec. #: / / Single Married Widowed Separated
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationBC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel
BC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel Protocol Code Tumour Group Contact Physician UGOOVBEVP Gynecologic Oncology Dr. Anna Tinker
More informationCHF for Clinician. AtHomeCare.com
CHF for Clinician AtHomeCare.com CONTACT INFORMATION FOR CLIENTS Client s Name: SOC Date: Case Manager s Name: Phone #: Physician s Name: Phone: Emergency Contact Person s Name: Phone Number: MISSION STATEMENT
More informationIvabradine in Inappropriate Sinus Tachycardia
UNIVERSITA DEGLI STUDI DI MILANO I.R.C.C.S POLICLINICO SAN DONATO CENTRO PER LO STUDIO E LA TERAPIA DELLLE MALATTIE CARDIOVASCOLARI E. MALAN Ivabradine in Inappropriate Sinus Tachycardia Riccardo Cappato,
More informationPropranolol RICHARD GORLIN. Boston, Mass., U.S.A. ventricular response to atrial fibrillation. Surprisingly,
Brit. Heart., 1967, 29, 305. Conversion of Atrial Fibrillation and Flutter by Propranolol STEVEN WOLFSON, MICHAEL V. HERMAN, JAY M. SULLIVAN, AND RICHARD GORLIN From the Medical Clinics and Cardiovascular
More informationazilsartan medoxomil
azilsartan medoxomil edarbi 40mg Tablet 80mg Tablet ANTIHYPERTENSIVE Angiotensin II Receptor Antagonist FORMULATION: Each tablet contains 40mg Azilsartan medoxomil (as potassium) Each tablet contains 80mg
More informationP. TURNER M.D., F.R.C.P. (Briant, Reid and Dollery, 1973), is impaired by. treatment with tricyclic antidepressant drugs. Since
Postgraduate Medical Journal (December 1974) 5, 729-733. Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness C. DE B. WHITE M.R.C.P. Summary In the treatment
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationLA CLINICA E LA DIAGNOSI DELLA VERTIGINE VASCOLARE
LA CLINICA E LA DIAGNOSI DELLA VERTIGINE VASCOLARE M. Mandalà Azienda Ospedaliera Universitaria Senese WHY ARE WE SCARED? NEED TO BETTER UNDERSTAND PATHOPHYSIOLOGY WHAT IS KNOWN WHAT IS EFFECTIVE and SIMPLE
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationPATIENT MEDICAL HISTORY FOR B.O.L.D. (Please check the most appropriate answer. If you have any questions please call the office for assistance)
Name: Date of Birth: Date: Race: Caucasion African American Hispanic Native American Pacific Islander PATIENT MEDICAL HISTORY FOR B.O.L.D. (Please check the most appropriate answer. If you have any questions
More informationPRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T
PRODUCT CIRCULAR Tablets I. THERAPEUTIC CLASS, the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1 ) antagonist. also provides a reduction in
More informationAdult Demographics Form
Adult Demographics Form Patient s Name: Preferred Name: Age: Patient s Social Security Number: Date of Birth: Sex: M / F Home Address: Apt: City: State: Zip: Cell phone #: Home Phone #: Work phone #: Email:
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationDefinition : Stages : ( RIFLE vs. AKIN ) Causes and classification : Pre-renal Renal Post- renal Clinical manifestations and Complication Management
AKI Definition : Stages : ( RIFLE vs. AKIN ) Causes and classification : Pre-renal Renal Post- renal Clinical manifestations and Complication Management and indications for RRT Etiology prerenal causes
More informationfor Medical Research. (Received May 10th, 1922.)
XLV. NOTE ON URINARY TIDES AND EXCRETORY RHYTHM. BY JAMES ARGYLL CAMPBELL AND THOMAS ARTHUR WEBSTER. From the Department of Applied Physiology, National Institute for Medical Research. (Received May 10th,
More informationhydrochlorothiazide in the treatment of moderate arterial
Br. J. clin. Pharmac. (1987), 23, 65S-69S Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension D. STERU1, M. CHILDS', S. LANCRENON',
More informationRoutine Clinic Lab Studies
Routine Lab Studies Routine Clinic Lab Studies With all lab studies, a Tacrolimus level will be obtained. These drug levels are routinely assessed to ensure that there is enough or not too much anti-rejection
More informationFelodipine vs hydralazine: a controlled trial as third line therapy
Br. J. clin. Pharmac. (1986), 21, 621-626 Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension CO-OPERATIVE STUDY GROUP* *Members of the co-operative study group were: Responsible
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationAdams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS
Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS Your health is important to us! The test descriptions listed below are for educational purposes only. Laboratory test interpretation
More informationMHD I SESSION X. Renal Disease
MHD I, Session X, Student Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD I SESSION X Renal Disease Monday, November 11, 2013 MHD I, Session X, Student Copy Page 2 Case #1 Cc: I have had weeks of diarrhea
More informationPRODUCT INFORMATION UROCIT -K. Wax matrix tablets
PRODUCT INFORMATION UROCIT -K Wax matrix tablets NAME OF DRUG Potassium Citrate CAS number- 6100-05-6 The empirical formula of potassium citrate is K 3 C 6 H 5 0 7.H 2 O, and its structural formula is:
More informationJune 8, 2018, London UK TREATMENT OF VASOVAGAL SYNCOPE
June 8, 2018, London UK TREATMENT OF VASOVAGAL SYNCOPE Where to go for help Syncope: HRS Definition Syncope is defined as: a transient loss of consciousness, associated with an inability to maintain postural
More informationAnne M. Calkins, 1 Joseph Shurman, 2 Mark Jaros, 3 Richard Kim, 4 Gwendoline Shang 4. New York Spine and Wellness Center, North Syracuse, NY; 2
Peripheral Edema and Weight Gain in Adult Patients With Painful Diabetic Peripheral Neuropathy Receiving Gabapentin Enacarbil or Pregabalin Enrolled in a Randomized, Phase 2 Trial Anne M. Calkins, 1 Joseph
More informationALONE AND IN COMBINATION IN MILD TO MODERATE
Br. J. clin. Pharmac. (1982),14,127S-131S COMPARISON OF CAPTOPRIL AND HYDROCHLOROTHIAZIDE ALONE AND IN COMBINATION IN MILD TO MODERATE ESSENTIAL HYPERTENSION MYRON H. WEINBERGER Indiana University Medical
More informationCASE-BASED SMALL GROUP DISCUSSION
MHD I, Session 11, Student Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD I SESSION 11 Renal Block Acid- Base Disorders November 7, 2016 MHD I, Session 11, Student Copy Page 2 Case #1 Cc: I have had
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationCASE-BASED SMALL GROUP DISCUSSION MHD II
MHD II, Session 11, Student Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD II Session 11 April 11, 2016 STUDENT COPY MHD II, Session 11, Student Copy Page 2 CASE HISTORY 1 Chief complaint: Our baby
More informationQ&A. DEMO Version
ACSM Exercise Specialist Exam Q&A DEMO Version Copyright (c) 2010 Chinatag LLC. All rights reserved. Important Note Please Read Carefully For demonstration purpose only, this free version Chinatag study
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationGASTROINESTINAL BLEEDING. Dr.Ammar I. Abdul-Latif
GASTROINESTINAL BLEEDING Dr.Ammar I. Abdul-Latif CLASSIFICATION OF G.I.BLEEDING GIB Appearance Acuity Site Apparent Acute Upper Obscure Chronic Lower UPPER&LOWER G.I.BLEEDING CAUSES OF UPPER G.I. BLEEDING
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationBeta Blockade: Protection or Panacea
Beta Blockade: Protection or Panacea Jason Axt Jason s Recommendations Perioperative β Blockade (BB) If on BB stay on If Vascular Sx + documented ischemia - start. 2+ risk factors - start Use in isolated
More informationAcid/Base Disorders 2015
Objectives - 2 1. Identify acid/base disorders 2. Discuss etiologies for 1 0 acid/base disorders (will not include mixed disorders) 3. Interpret acid/base disorders by interpreting arterial blood gas &
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationPotassium-Sparing Effects of Triamterene in the Treatment of Hypertension
Potassium-Sparing Effects of Triamterene in the Treatment of Hypertension Downloaded from http://ahajournals.org by on November 1, 218 By RALPH E. SPIEKERMAN, M.D., KENNETH G. BERGE, M.D., DELORAN L. THURBER,
More informationCalcium (Ca 2+ ) mg/dl
Quick Guide to Laboratory Values Use this handy cheat-sheet to help you monitor laboratory values related to fluid and electrolyte status. Remember, normal values may vary according to techniques used
More informationBC Cancer Protocol Summary for Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine
BC Cancer Protocol Summary for Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine Protocol Code Tumour Group Contact Physician CNBEV
More informationDrug-Induced Diabetes May Not Be Harmful But Should Be Prevented. Jeffrey A. Cutler, MD, MPH
Drug-Induced Diabetes May Not Be Harmful But Should Be Prevented Jeffrey A. Cutler, MD, MPH Overview Focus on thiazide-like diuretics (not BB) Diuretic-induced versus diureticassociated diabetes Role of
More informationAntihypertensive and biochemical effects
Antihypertensive and biochemical effects of chlorthalidone Thirty-seven patients with mild to moderate essential hypertension completed a dose-finding study in which daily doses of 25, 50, 100, and 200
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationLABETALOL IN SEVERE AND RESISTANT HYPERTENSION
Br. J. clin. Pharmac. (1979), 8, 13S-17S LABETALOL IN SEVERE AND RESISTANT HYPERTENSION King's College Hospital Renal Unit, Dulwich Hospital, London SE22 8PT, UK 1 The efficacy of labetalol in the treatment
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationSupplement Table 1. Definitions for Causes of Death
Supplement Table 1. Definitions for Causes of Death 3. Cause of Death: To record the primary cause of death. Record only one answer. Classify cause of death as one of the following: 3.1 Cardiac: Death
More informationClinicalTrials.gov Identifier: NCT Sponsor/company: Sanofi-Aventis. Date: 08/02/ 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Sanofi-Aventis ClinicalTrials.gov
More informationSubject ID: I N D # # U A * Consent Date: Day Month Year
IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be
More informationKeeping track of your numbers
Keeping track of your numbers If you have relapsed or refractory multiple myeloma, keeping track of your numbers can help you take an active role in your care. It s also one way you and your doctor can
More informationHypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to
Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to 90 mmhg. These pressures are called Normal blood pressure
More informationACID/BASE. A. What is her acid-base disorder, what is her anion gap, and what is the likely cause?
These fluid and electrolyte problems are modified from those in a previous textbook for this sequence, Renal Pathophysiology edited by James A. Shayman M.D., Professor of Internal Medicine, University
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationUnderstanding Blood Tests
PATIENT EDUCATION patienteducation.osumc.edu Your heart pumps the blood in your body through a system of blood vessels. Blood delivers oxygen and nutrients to all parts of the body. It also carries away
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationTKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients. Moustafa Sameer Hematology Medical Advsior,Novartis oncology
TKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients Moustafa Sameer Hematology Medical Advsior,Novartis oncology Introduction In people with chronic myeloid leukemia, A
More informationContrast media Purpose of using contrast Contrast reaction Nephrotoxicity from contrast Nephrogenic systemic fibrosis When should contrast be used
Contrast vs Non-Contrast When to Order Stephen McManus, M.D. Contrast media Purpose of using contrast Contrast reaction Nephrotoxicity from contrast Nephrogenic systemic fibrosis When should contrast be
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More informationTables of Normal Values (As of February 2005)
Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationANY FAMILY HISTORY OF ANEURYSM OR DVT?
NAME: D/O/B: DATE: MR# WHAT PROBLEM(S) BRINGS YOU HERE TODAY? WHO SENT YOU TO US? DOCTOR/OTHER WHICH DOCTOR? WHAT SURGERY HAVE YOU HAD AND WHEN? (LIST) 1. 2. 3. 4. 5. 6. 7. HOW MUCH ALCOHOL DO YOU DRINK
More informationUnderstanding Congestive Heart Failure
Understanding Congestive Heart Failure Your health care team offers this information to help you and your family cope with congestive heart failure. It defines congestive heart failure, discusses ways
More informationAddress City State Zip. Home Phone Cell Work. (For SHPT use only) Emergency Contact Phone
Somerset Hills Physical Therapy, PC 180 Mount Airy Road, Suite 103 Basking Ridge, NJ 07920 Phone (908) 766-1407 Fax (908) 953-8454 wwwsomersethillsptcom Patient Information: Name Sex M F Date of Birth
More informationBlood Pressure Management in Acute Ischemic Stroke
Blood Pressure Management in Acute Ischemic Stroke Kimberly Clark, PharmD, BCCCP Clinical Pharmacy Specialist Critical Care, Greenville Health System Adjunct Assistant Professor, South Carolina College
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationHypertensives Emergency and Urgency
Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of
More informationAutonomic Nervous System (ANS) وحدة اليوزبكي Department of Pharmacology- College of Medicine- University of Mosul
Autonomic Nervous System (ANS) د. م. أ. وحدة اليوزبكي Department of Pharmacology- College of Medicine- University of Mosul Sympathetic (Adrenergic) nervous system 3 Objectives At end of this lecture, the
More informationComposition: Each Tablet contains. Pharmacokinetic properties:
Composition: Each Tablet contains Torsemide 5/10/20/40/100mg Pharmacokinetic properties: Torsemide is well absorbed from the gastrointestinal tract. Peak serum concentrations are achieved within 1 hour
More informationCRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT
CRRT Fundamentals Pre-Test AKI & CRRT 2017 Practice Based Learning in CRRT Question 1 A 72-year-old man with HTN presents to the ED with slurred speech, headache and weakness after falling at home. He
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationHYPERTENSION. Background for understanding the Hypertension literature. Case presentation. Approach to Treatment. Jeffrey J. Kaufhold, MD Nephrology
HYPERTENSION Background for understanding the Hypertension literature. Case presentation Approach to Treatment Jeffrey J. Kaufhold, MD Nephrology 2009 HYPERTENSION SUMMARY Background for understanding
More informationBIOCHEMICAL REPORT. Parameters Unit Finding Normal Value. Lipase U/L Amylase U/L
Lipase U/L 88.9 10-195 Amylase U/L 1181.1 371.3-1192.6 West Delhi :- 7/148, Opp. MCD Office, Major Pankaj Batra Marg, Near Ramesh Nagar, New Delhi-15, Ph. : 011-47562566,9999830187 Liver Function Test
More informationLOZAR. Composition Each tablet contains Losartan potassium 50 mg.
LOZAR Composition Each tablet contains Losartan potassium 50 mg. Tablets Action Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is
More informationOPEN EVALUATION OF LABETALOL IN THE TREATMENT OF ANGINA PECTORIS OCCURRING IN HYPERTENSIVE PATIENTS
Br. J. clin. Pharmac. (1979), 8, 25S-29S OPN VALUATION OF LABTALOL IN TH TRATMNT OF ANGINA PTORIS ORRING IN HYPRTIV PATINTS.M.M. BSTRMAN & M. SPNR ardiological Department, St Mary's Hospital, Norfolk Place,
More informationDEFINITIONS FOR FLUID STATUS & TARGET WEIGHT
Home Dialysis Interest Group HEALTHCARE TEAM TOOL DEFINITIONS FOR STATUS & TARGET WEIGHT BALANCED EXCESS DEFICIT Illustrations provided by: 1 BALANCE OF THE HOME HEMODIALYSIS PATIENT Dialysis Weight**
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002-01 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationInstruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy
Assessment Prior to administration: Assess patient for chest pain, dysrhythmias, and vital signs (initially and throughout therapy) Obtain complete medical history, including allergies, especially heart
More information